Phase I clinical trial - Phases précoces tumeurs solides

ARROW (BLU-667-1101)
Phases précoces tumeurs solides
Ouvert depuis le: 10.16.2021
Site: Paris
Public cible
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Description de l'essai

This is a Phase 1, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU-667 administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.